Meeting
2022 ASCO Annual Meeting
Abemaciclib in metastatic or locally advanced anaplastic thyroid cancer.
Authors
Vishesh Khanna
Stanford Cancer Center, Palo Alto, CA
Vishesh Khanna , Cristy Miles , Vandana Sundaram , Siddharth Sheth , Martina Steffen , Savanna Biedermann , Dhayoung Jun , Elizabeth Winters , Saad A. Khan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT04552769
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS6112)
DOI
10.1200/JCO.2022.40.16_suppl.TPS6112
Abstract #
TPS6112
Poster Bd #
96a
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC).
First Author: Bernard Tawfik
Poster
2023 ASCO Annual Meeting
Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors.
First Author: Jesús Fuentes Antrás
Poster
2023 ASCO Annual Meeting
Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment.
First Author: Seth Andrew Wander
Poster
2023 ASCO Annual Meeting
Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative.
First Author: Elisa Agostinetto